Zevra Therapeutics Shares Surge on $50M Asset Sale
Rare disease specialist becomes debt-free after disposing of SDX portfolio and resolving litigation
Zevra Therapeutics shares jumped 5.3% on Monday after the rare disease company announced it had sold its serdexmethylphenidate (SDX) portfolio to Commave Therapeutics for $50 million, a transaction that resolves pending litigation and eliminates the company's remaining debt obligations.
The deal includes Zevra's entire SDX portfolio, encompassing AZSTARYS® and KP1077, with $25 million payable upfront and an additional $25 million due shortly after closing. The agreement also settles a lawsuit Commave filed in Delaware Chancery Court in 2024, stemming from a 2019 license agreement between the companies.
Zevra used proceeds from the transaction to repay the principal balance on its $63 million term loan, resulting in a debt-free balance sheet, according to the company's announcement. The move provides increased financial and strategic flexibility as Zevra focuses on its rare disease pipeline.
Neil F. McFarlane, Zevra's President and Chief Executive Officer, characterized the agreement as mutually beneficial. "We are pleased to have reached a mutually beneficial agreement with Commave that resolves the pending litigation and enables us to focus on our mission of providing therapies for rare diseases," McFarlane stated in the press release. "We have had a productive partnership with Commave and have confidence in their ability to manage these programs going forward."
The asset sale represents a strategic pivot for the Celebration, Florida-based company, which has been transitioning into a commercial-stage specialty pharmaceutical company. In 2025, Zevra achieved a dramatic financial turnaround, reporting net income of $83.2 million on revenue of $106.5 million—a significant improvement from a net loss of $105.5 million in the previous year, according to company financial results.
That transformation was largely driven by the commercial success of MIPLYFFA, the company's treatment for Niemann-Pick disease type C, which generated $87.4 million in sales during fiscal year 2025. The company also bolstered its cash position in 2025 by selling a Priority Review Voucher for approximately $100 million, contributing to a year-end cash balance of $238.9 million.
Analysts have maintained a positive outlook on Zevra following its financial recovery. The stock currently carries a consensus "Moderate Buy" rating with an average price target of $22.75, according to market data—representing significant upside from Monday's trading level around $10.50. Eight analysts cover the stock, with two rating it a "Strong Buy" and six rating it a "Buy." No analysts currently recommend holding or selling the shares.
Zevra's market capitalization stands at approximately $562 million, with the stock trading within its 52-week range of $6.19 to $13.16. Institutional investors hold 65.8% of outstanding shares, indicating strong institutional support for the company's strategic direction.
The disposal of the SDX portfolio simplifies Zevra's business model, allowing management to concentrate resources on rare disease treatments. This strategic focus aligns with the company's stated mission and may improve operational efficiency by eliminating the complexity of managing the attention-deficit/hyperactivity disorder (ADHD) franchise included in the sold assets.
Removing the litigation overhang and debt obligations should reduce balance sheet risk at a time when biotechnology companies face increasing scrutiny from investors regarding cash runway and financial sustainability. The transaction demonstrates Zevra's ability to monetize non-core assets while maintaining its primary focus on rare disease therapeutics, a sector that continues to attract investment despite broader market volatility.
Looking ahead, investors will be watching for updates on MIPLYFFA's commercial trajectory and any developments in Zevra's rare disease pipeline. With a strengthened financial position and simplified operational focus, the company appears well-positioned to execute its growth strategy in the specialty pharmaceutical market.